Shorter post-infusion cooling times at least as effective as longer cooling times — An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-09526-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Florine F I Breed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands…. Hauptthemen laut MEDLINE: Alopecia, Antineoplastic Combined Chemotherapy Protocols, Hypothermia, Induced. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Chemotherapy-induced alopecia (CIA), a very common and distressing side effect of cancer treatment can be effectively prevented by scalp cooling. The aim of this observational study was to estimate the effect of post-infusion cooling time (PICT) on wearing a head cover for taxane- and anthracycline-based chemotherapies. METHODS: The Dutch Scalp Cooling Registry (DSCR), which started in January 2006, collected data from 4680 scalp-cooled patients across 68 Dutch hospitals. Questionnaires on patient, chemotherapy and scalp cooling characteristics were completed by patients and nurses. The patient-reported primary outcome included the use of head covering during the final scalp cooling session. Analysis included patients who had received Docetaxel 75 or 100 mg/m2 (D75 or D100), Paclitaxel 70-90 or 160-180 mg/m2 (T70-90 or T160-180), Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 (AC), or 5-Fluorouracil 500 mg/m2 Epirubicin 90 or 100 mg/m2 and Cyclophosphamide 500 mg/m2 (FE90C or FE100C). RESULTS: Shorter post-infusion cooling times (< 85 minutes) seem to be sufficient for maintaining scalp cooling effectiveness in the chemotherapy regimens studied, with no added benefit from extending cooling time beyond this threshold. CONCLUSION: For all anthracycline and taxane-based chemotherapy regimens studied, shorter PICTs delivered comparable results to longer PICTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. florine@grepponblanc.eu.
- Catharina Hospital, Eindhoven, The Netherlands.
- Department of Medical Oncology, Máxima Medical Centre, Eindhoven, The Netherlands.
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
- Max Planck Institute for Demographic Research, Rostock, Germany.
- PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Zitieren
APA
Breed, F. F. I., Breed, W. P. M., Dercksen, M. W., Ezendam, N., Bijlsma, M. J., & van den Hurk, C. J. G. (2025). Shorter post-infusion cooling times at least as effective as longer cooling times — An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09526-2
Vancouver
Breed FFI, Breed WPM, Dercksen MW, Ezendam N, Bijlsma MJ, van den Hurk CJG. Shorter post-infusion cooling times at least as effective as longer cooling times — An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09526-2
BibTeX
@article{Breed2025,
author = {Breed, Florine F I and Breed, Wim P M and Dercksen, Marcus W and Ezendam, Nicole and Bijlsma, Maarten J and van den Hurk, Corina J G},
title = {Shorter post-infusion cooling times at least as effective as longer cooling times — An observational study of taxane- and anthracycline-based chemotherapies in the Dutch Scalp Cooling Registry},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-09526-2}
}
EUVIMED